When IBS treatment stops working, or never worked well in the first place, the question shifts from 'how do I manage my IBS?' to 'is this actually IBS?' One of the most important conditions to rule out is inflammatory bowel disease. IBD requires different treatment, carries different risks, and has specific tests that can identify it. This article walks through the testing options in order, from non-invasive screening to advanced imaging, so you know what to request and why.
When Should You Start Asking About IBD Testing?
There is no universal timeline, but the following situations warrant a conversation with your doctor about IBD-specific testing.
- Your IBS symptoms have not improved after 3 to 6 months of appropriate treatment (dietary changes, medication, lifestyle modifications).
- Your symptoms have changed character. New bleeding, weight loss, nocturnal symptoms, or fevers are red flags.
- You were diagnosed with IBS without any objective testing (no blood work, no stool tests, no endoscopy).
- You have a family history of IBD in a first-degree relative.
- You have extraintestinal symptoms that are associated with IBD: joint pain, skin rashes (erythema nodosum, pyoderma gangrenosum), eye inflammation (uveitis), or mouth ulcers.
- You are under 35 and your symptoms started abruptly or after an apparent infection.
Step 1: Fecal Calprotectin (Stool Test)
Fecal calprotectin is the single most useful non-invasive test for distinguishing IBD from IBS. It measures a protein (calprotectin) released by neutrophils in the intestinal lining. When there is active inflammation in the gut, calprotectin levels rise. In IBS, where there is no structural inflammation, calprotectin is normal.
The test involves a single stool sample, which can often be collected at home and dropped off at a lab. Results are reported in micrograms per gram (mcg/g). The commonly used cutoffs are: below 50 mcg/g is considered normal and makes active IBD very unlikely; 50 to 150 mcg/g is a gray zone that may warrant repeat testing or further investigation depending on clinical context; above 150 mcg/g is elevated and warrants referral for colonoscopy. A meta-analysis by van Rheenen et al. (2010) in the BMJ found that at a 50 mcg/g cutoff, fecal calprotectin had 93% sensitivity and 96% specificity for IBD in adults with suspected disease.
âšī¸Several factors can falsely elevate fecal calprotectin: NSAIDs (ibuprofen, naproxen), proton pump inhibitors, and active gastrointestinal infections. If your result is borderline, your doctor may ask you to stop NSAIDs for 2 weeks and retest before proceeding to colonoscopy.
Step 2: Blood Markers (CRP, ESR, CBC)
Blood tests are a useful complement to fecal calprotectin but should not be used as the sole screening tool for IBD. Here is what each marker tells you.
- CRP (C-reactive protein): A marker of systemic inflammation produced by the liver. Elevated CRP (above 5 mg/L in most labs) suggests active inflammation somewhere in the body. CRP is elevated in approximately 70 to 80% of active Crohn's disease flares and about 50% of UC flares (Vermeire et al., 2006). However, normal CRP does not rule out IBD. Mild or isolated ileal Crohn's may not generate enough systemic inflammation to elevate CRP.
- ESR (erythrocyte sedimentation rate): Another inflammation marker. Less specific than CRP but adds value when interpreted alongside other results. Elevated in active IBD but also in infections, autoimmune diseases, and other inflammatory conditions.
- CBC (complete blood count): Can reveal anemia (low hemoglobin), particularly iron deficiency anemia from chronic blood loss. Elevated platelets (thrombocytosis) and elevated white blood cells can also indicate active inflammation.
- Iron studies (serum ferritin, transferrin saturation): Unexplained iron deficiency, especially in young patients or men, should raise suspicion for occult GI blood loss from IBD.
- Albumin: Low albumin can indicate protein loss from inflamed bowel (protein-losing enteropathy) or malnutrition from active IBD.
The key limitation of blood tests is that they are not specific to the gut and can be normal in mild IBD. A study by Vermeire et al. (2006) in Gut found that CRP was normal in approximately 20 to 30% of patients with endoscopically confirmed active Crohn's disease. This is why blood tests should be paired with fecal calprotectin, not used alone.
Step 3: Colonoscopy with Biopsies
If fecal calprotectin is elevated, blood markers are abnormal, or clinical suspicion remains high despite normal non-invasive tests, colonoscopy is the next step. Colonoscopy allows direct visualization of the colonic mucosa and terminal ileum, and enables tissue sampling (biopsies) for microscopic evaluation.
For IBD evaluation, several points about the procedure are important to understand.
- Ileal intubation is essential: The endoscopist should advance into the terminal ileum, which is the most common site of Crohn's disease. A colonoscopy that only examines the colon can miss terminal ileal Crohn's.
- Segmental biopsies should be taken: ECCO-ESGAR guidelines (Maaser et al., 2019) recommend taking biopsies from at least 5 sites throughout the colon and terminal ileum, including from both abnormal and normal-appearing mucosa. Microscopic inflammation can be present even when the mucosa looks grossly normal.
- Biopsy results matter more than visual appearance: The pathologist examines the tissue for features characteristic of IBD, including crypt architectural distortion, basal plasmacytosis, granulomas (Crohn's), and chronic inflammatory infiltrate. These findings can be present before visible ulceration develops.
- Random biopsies from normal-appearing mucosa are not always performed: If your colonoscopy report does not mention biopsies, ask whether they were taken. A visually normal scope without biopsies does not fully rule out IBD.
â ī¸When scheduling a colonoscopy to evaluate for IBD, confirm with your gastroenterologist that the plan includes ileal intubation and segmental biopsies from multiple sites. This is standard practice for IBD evaluation but may not be routine for other indications.
Step 4: Capsule Endoscopy for Small Bowel Crohn's
Standard colonoscopy visualizes the colon and the last few centimeters of the small intestine (terminal ileum). That leaves approximately 6 meters of small bowel unexamined. Crohn's disease can occur anywhere in the small bowel, and in some patients the disease is entirely proximal to the terminal ileum, making it invisible on colonoscopy.
Capsule endoscopy addresses this gap. The patient swallows a pill-sized camera that takes thousands of images as it travels through the entire small intestine. These images are transmitted to a recorder worn on the body and later reviewed by a gastroenterologist. Capsule endoscopy has a diagnostic yield of 55 to 71% for detecting small bowel Crohn's disease in patients with suspected disease and a non-diagnostic colonoscopy (Defined et al., 2013). It can identify mucosal ulcers, erosions, erythema, and strictures that other tests miss.
- Capsule endoscopy is typically requested when: colonoscopy and upper endoscopy are non-diagnostic but clinical suspicion for small bowel Crohn's remains high; fecal calprotectin is persistently elevated without an explanation; or the patient has symptoms suggesting small bowel involvement (mid-abdominal pain, vitamin deficiencies, unexplained anemia).
- Before capsule endoscopy, a patency capsule or cross-sectional imaging (MR enterography or CT enterography) is usually performed to rule out significant strictures that could trap the capsule.
- The main limitation is that capsule endoscopy cannot take biopsies. If it identifies suspicious findings, a further procedure (balloon-assisted enteroscopy or surgery) may be needed for tissue confirmation.
Step 5: MR Enterography (MRE)
MR enterography is an MRI-based imaging technique specifically designed to evaluate the small bowel. It provides detailed cross-sectional images of the bowel wall, mesentery, and surrounding structures without radiation exposure. This makes it particularly suitable for young patients who may need repeated imaging over their lifetime.
MRE can identify wall thickening, mural enhancement (indicating active inflammation), strictures, fistulas, abscesses, and mesenteric lymph node enlargement. ECCO-ESGAR guidelines recommend MRE as the first-line cross-sectional imaging modality for evaluating the small bowel in suspected or established Crohn's disease (Defined et al., 2017). It is also useful for assessing the extent of disease, detecting complications, and monitoring treatment response.
- MRE requires the patient to drink a large volume of oral contrast (typically 1 to 1.5 liters) to distend the small bowel, followed by an MRI scan that takes 30 to 45 minutes.
- MRE is better than capsule endoscopy for detecting transmural and extramural disease (fistulas, abscesses, mesenteric changes) but may miss very superficial mucosal changes that capsule endoscopy would detect.
- CT enterography (CTE) is an alternative when MRE is unavailable or contraindicated, but it involves ionizing radiation and is less preferred for young patients and for repeated imaging.
What Helps You Prepare for These Conversations?
When you walk into a GI appointment asking about IBD testing, the quality of your symptom history matters. Gastroenterologists make testing decisions based on symptom patterns, duration, severity, and response to prior treatment. The more specific and organized your history, the more efficiently they can determine which tests are appropriate.
- Track your symptoms for at least 2 to 4 weeks before your appointment: what symptoms you have, when they occur, what makes them better or worse, and how severe they are on a consistent scale.
- Note any red flag symptoms specifically: blood in stool (color, frequency, amount), weight changes, fevers, nocturnal symptoms.
- Bring a list of all IBS treatments you have tried, how long you used each one, and whether it helped.
- Note any extraintestinal symptoms: joint pain, skin changes, eye redness, mouth ulcers.
- The GLP1Gut app can help you log symptoms, bowel movements, and food intake in a format that is easy to share with your doctor.
A Practical Testing Sequence
Not every patient needs every test. Here is a reasonable step-by-step approach for someone whose IBS treatment is not working.
- Start with fecal calprotectin and blood work (CRP, CBC, iron studies). These are non-invasive, relatively inexpensive, and available through most primary care offices.
- If calprotectin is below 50 mcg/g and blood work is normal, active IBD is unlikely. Consider other causes of refractory IBS symptoms (SIBO, celiac disease, bile acid malabsorption, microscopic colitis).
- If calprotectin is above 150 mcg/g or blood work shows inflammation or anemia, refer for colonoscopy with ileal intubation and segmental biopsies.
- If colonoscopy is normal but clinical suspicion for small bowel Crohn's remains (persistent calprotectin elevation, vitamin deficiencies, mid-abdominal symptoms), request capsule endoscopy or MR enterography.
- If calprotectin is in the gray zone (50 to 150 mcg/g), consider repeating the test after stopping NSAIDs. Persistent borderline elevation may warrant colonoscopy.
âšī¸This testing sequence is not rigid. Your gastroenterologist may adjust the order based on your specific symptoms, risk factors, and clinical judgment. The goal is to have a plan rather than continuing to treat unresponsive IBS without investigating further.
How much does fecal calprotectin testing cost?
In the United States, the out-of-pocket cost for fecal calprotectin testing typically ranges from $50 to $200 without insurance. Most commercial insurance plans cover the test when ordered for clinical suspicion of IBD or to differentiate IBD from IBS. Medicare covers it in appropriate clinical contexts. In the UK, it is available through the NHS as recommended by NICE guidelines. The cost of the test is minimal compared to the cost of an unnecessary colonoscopy or years of misdirected IBS treatment.
Can I request these tests from my primary care doctor, or do I need a gastroenterologist?
Fecal calprotectin, CRP, CBC, and iron studies can all be ordered by a primary care physician. You do not need a gastroenterologist for initial screening. If results are abnormal, your PCP will typically refer you to a gastroenterologist for colonoscopy and further workup. In some cases, if you have difficulty getting a GI referral, bringing abnormal screening results can help expedite the process.
What does a capsule endoscopy feel like?
Capsule endoscopy is non-invasive and generally well tolerated. You swallow a pill-sized camera (about the size of a large vitamin) with water. There is no sedation, no discomfort during the procedure, and you can go about your normal day while wearing a small recording device on a belt. The capsule passes naturally in a bowel movement within 24 to 48 hours. The main preparation is fasting beforehand (typically 12 hours) and sometimes a bowel prep to ensure clear images.
What if my doctor says further testing is not necessary?
If your IBS treatment is failing and you have never had inflammatory markers checked, it is reasonable to advocate for basic screening (calprotectin, CRP, CBC). Frame the request in clinical terms: you want to confirm that inflammatory causes have been excluded before continuing symptomatic management. If your doctor disagrees, ask for the reasoning and whether they would be willing to document the decision in your chart. You also have the option of seeking a second opinion from a gastroenterologist if your current provider is not responsive to your concerns.
How long does it take to get results from these tests?
Blood tests (CRP, CBC, iron studies) typically return within 1 to 3 days. Fecal calprotectin results usually take 3 to 7 days depending on the lab. Colonoscopy biopsies take 5 to 14 days for pathology results. Capsule endoscopy interpretation can take 1 to 2 weeks. MR enterography radiology reports are usually available within a few days. If you are waiting longer than these timeframes, follow up with your doctor's office.